{"anticipatedPostingDate":"2027-11","denomUnitsSelected":"Participants","description":"To evaluate the efficacy of the selumetinib granule formulation by assessment of Objective Response Rate","reportingStatus":"NOT_POSTED","timeFrame":"At screening, at week 17 (Cycle5 Day1), week 33 (Cycle9 Day1), week 49 (Cycle13 Day1), week 73 (Cycle19 Day1) and week 97 (Cycle25 Day1), end of treatment (each cycle is 28 days)","title":"Objective Response Rate","type":"SECONDARY"}